Institutional Investors Must Be Pleased After a 8.9% Gain Last Week That Adds to CRISPR Therapeutics AG's (NASDAQ:CRSP) One-year Returns

Yahoo FinanceJul 18 07:47 ET

CRISPR Therapeutics (CRSP) Moves 9.2% Higher: Will This Strength Last?

Zacks Jul 17 06:10 ET

CRISPR Therapeutics (NASDAQ:CRSP) Adds US$359m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 54%

Investing in stocks inevitably means buying into some companies that perform poorly. But long term CRISPR Therapeutics AG (NASDAQ:CRSP) shareholders have had a particularly rough ride in the last

Simply Wall StJul 16 15:52 ET

Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?

Yahoo FinanceJul 16 04:15 ET

Ark's Cathie Wood Blasts Big Tech. She Prefers Palantir and These Other Stocks.

Cathie Wood's flagship ARK Innovation exchange-traded fund is 72% below its peak while the S&P 500 is hitting all-time highs.

BarronsJul 11 09:04 ET

Cathie Wood Touts Palantir, Coinbase And Roku As ARK's Flagship Fund Shifts Focus From Mag 6 Amid 'Whiff' Of Lower Interest Rates

In a recent letter to investors, Cathie Wood, the CEO of ARK Invest, highlighted the potential of the company's flagship fund, ARK Innovation ETF (NYSE:ARKK), despite its recent underperformance.

BenzingaJul 11 07:15 ET